Recce Pharmaceuticals doses all patients in Phase 2 clinical trial...
Recce Pharmaceuticals Ltd has successfully wrapped up dosing of all 30 patients in its Phase 2 clinical trial of RECCE® 327 Topical Gel (R327G) for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). New class of anti-infectives …